Identification and follow-up of pregnant women with platelet-type human platelet antigen (HPA)-1bb alloimmunized with fetal HPA-1a
- PMID: 30154886
- PMCID: PMC6111341
- DOI: 10.5114/aoms.2016.63600
Identification and follow-up of pregnant women with platelet-type human platelet antigen (HPA)-1bb alloimmunized with fetal HPA-1a
Abstract
Introduction: Pregnant women negative for human platelet antigen 1a (HPA-1a) are at risk of alloimmunization with fetal HPA-1a antigen inherited from the father, and their offspring may develop fetal and neonatal alloimmune thrombocytopenia (FNAIT). The aim of this study was to analyze the frequency of HPA-1a alloimmunization in pregnant Polish women, the feasibility of using maternal platelets for intrauterine transfusions in women subjected to diagnostic fetal blood sampling (FBS) and to discuss potential consequences of alloimmunization.
Material and methods: Fifteen thousand two hundred and four pregnant women were typed for HPA-1a; HPA-1a negative were screened for anti-HPA-1a. Alloimmunized women received specialist perinatology care; some of them were subjected to FBS, followed by transfusion of HPA-1a negative platelet concentrates (PC) prepared from maternal blood.
Results: Three hundred seventy-three (2.5%) women were HPA-1a negative, and 32 (8.6%) tested positively for anti-HPA-1a. Antibodies were detected in 22 women during pregnancy. Diagnostic FBS followed by PC transfusion was performed in 14 woman, who were platelet donors for their 16 unborn babies. Blood donations were tolerated well by the patients, and also intrauterine platelet transfusions were uneventful. Pharmacotherapy with intravenous immunoglobulins was implemented in 11/22 patients.
Conclusions: HPA-1a negative women (ca. 2.5% of all pregnant patients) are at risk of alloimmunization with HPA-1a antigen and developing FNAIT. Alloimmunized women can be donors of platelets for their offspring providing removal of antibodies from PC. Owing to potential complications, special care should be taken if an alloimmunized woman was qualified as a blood or stem cell recipient.
Keywords: HPA-1a cohort study; anti-human platelet antigen 1a antibodies; fetal/neonatal alloimmune thrombocytopenia; platelet transfusions.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Fetal and Neonatal Alloimmune Thrombocytopenia-New Prospects for Fetal Risk Assessment of HPA-1a-Negative Pregnant Women.Transfus Med Rev. 2020 Oct;34(4):270-276. doi: 10.1016/j.tmrv.2020.09.004. Epub 2020 Sep 16. Transfus Med Rev. 2020. PMID: 33039264 Review.
-
Fetal exposure to maternal human platelet antigen-1a does not induce tolerance. An analytical observational study.PLoS One. 2017 Aug 24;12(8):e0182957. doi: 10.1371/journal.pone.0182957. eCollection 2017. PLoS One. 2017. PMID: 28837581 Free PMC article.
-
The prevalence of HPA-1a alloimmunization and the potential risk of FNAIT depend on both the DRB3*01:01 allele and associated DR-DQ haplotypes.Scand J Immunol. 2020 Jul;92(1):e12890. doi: 10.1111/sji.12890. Epub 2020 May 17. Scand J Immunol. 2020. PMID: 32299122
-
What's with the boys? Lower birth weight in boys from HPA-1a alloimmunized pregnancies - New insights from a large prospective screening study in Poland.J Reprod Immunol. 2023 Dec;160:104168. doi: 10.1016/j.jri.2023.104168. Epub 2023 Nov 7. J Reprod Immunol. 2023. PMID: 37992463
-
Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review.Vox Sang. 2019 Jan;114(1):79-94. doi: 10.1111/vox.12725. Epub 2018 Nov 22. Vox Sang. 2019. PMID: 30565711
Cited by
-
Antigen-specific immunotherapy for platelet alloimmune disorders.Hum Immunol. 2024 Nov;85(6):111172. doi: 10.1016/j.humimm.2024.111172. Epub 2024 Nov 8. Hum Immunol. 2024. PMID: 39520801 Review.
References
-
- Husebekk A. Fetal/neonatal alloimmune thrombocytopenia (FNAIT) Vox Sang. 2011;101:1–1.
-
- Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1:363–6. - PubMed
-
- Sachs UJ. Fetal/neonatal alloimmune thrombocytopenia. Thromb Res. 2013;131(Suppl 1):S42–6. - PubMed
-
- Uhrynowska M, Dębska M, Guz K, et al. Zapobieganie alloimmunologicznej małopłytkowości płodów/noworodków (AIMPN) w Polsce – program PREVFNAIT. Ginekol Pol. 2015;86:62–6. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources